Skip to content

Development and clinical research of a new radionuclide imaging agent for primary aldosteronism

Development and clinical research of a new radionuclide imaging agent for primary aldosteronism

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092739
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism

Interventions

Primary aldosteronism group:Primary aldosteronism

Sponsors

Wuxi people’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1.Patients>=18 years of age, informed consent, diagnosed with primary aldosteronism and willingness to undergo surgery, meet one of the following criteria; 2.Adrenal CT showing the presence of multiple nodular or hyperplastic lesions unilaterally or bilaterally; 3.Adrenal CT showing unilateral or bilateral nodular hyperplasia. 4.Adrenal CT showed a unilateral single nodule except for young patients age 35 years with a combination of spontaneous hyperkalemia marked hypersecretion of aldosterone and CT features consistent with a unilateral adenoma according to international guidelines and except for patients with a plasma aldosterone concentration of 20 ngdL a plasma renin concentration of 5 IUmL a plasma potassium concentration of 3.5 mmolL and an adrenal unilateral nodule of 1 cm in diameter contralateral side was normal according to a national study;

Exclusion criteria

Exclusion criteria: 1.Combination of severe hepatic insufficiency congenital heart disease malignant tumors and severe infections; 2.Patients with severe mental illness or cognitive impairment; 3.Not easy to follow up, not able to provide informed consent, etc. 4.Those who, in the opinion of the researcher, are not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Plasma aldosterone;

Secondary

MeasureTime frame
Plasma renin;Blood pressure;Serum potassium;Plasma cortisol;Plasma adrenocorticotropic hormore;

Countries

China

Contacts

Public ContactXiaowei Zhu

Wuxi people’s Hospital

1766990886@qq.com+86 510 85350883

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026